Potential biomarkers for anti-EGFR therapy in metastatic colorectal cancer

@article{Yang2016PotentialBF,
  title={Potential biomarkers for anti-EGFR therapy in metastatic colorectal cancer},
  author={Jiao Yang and Shuting Li and Biyuan Wang and Yinying Wu and Zheling Chen and Meng Lv and Yayun Lin and Jin Yang},
  journal={Tumor Biology},
  year={2016},
  volume={37},
  pages={11645-11655}
}
Anti-epidermal growth factor receptor (EGFR) therapy has established efficacy in metastatic colorectal cancer, but a significant number of patients do not respond to such treatment. Recently, various biomarkers were reported to be useful in predicting resistance to anti-EGFR. All the potential biomarkers predicting resistance to anti-EGFR are reviewed herein from five aspects. First, upstream molecules, including epiregulin (EREG) and amphiregulin (AREG), might play different roles according to… Expand
Prognostic and predictive role of EGFR pathway alterations in biliary cancer patients treated with chemotherapy and anti-EGFR
TLDR
The alterations found in this work seem to have a prognostic impact rather than a predictive role towards anti-EGFR therapy, and the presence of mutations in EGFR or in its transducers did not affect PFS or OS, while the extrahepatic cholangiocarcinoma patients had a worse prognosis compared to WT. Expand
Preferential Response of Basal-Like Head and Neck Squamous Cell Carcinoma Cell Lines to EGFR-Targeted Therapy Depending on EREG-Driven Oncogenic Addiction
TLDR
Interestingly, it is shown that EGFR blockade inhibits EREG expression, and that EREG knock-down decreases basal cell clonogenic survival, suggesting that E REG expression could be a predictive functional marker of sensitivity to EG FR blockade in basal-like HNSCC. Expand
Mechanisms of Cetuximab Resistance and How to Overcome It
Deregulated or increased signalling of the epidermal growth factor receptor (EGFR) plays an integral role in the development of various cancer types, including head and neck squamous cell carcinomaExpand
Pre-treatment inflammatory indexes as predictors of survival and cetuximab efficacy in metastatic colorectal cancer patients with wild-type RAS
TLDR
Pre-treatment inflammatory indexes, especially NLR were potential biomarkers to predict the survival of mCRC patients with cetuximab therapy, and were associated with survival in the univariate analysis. Expand
The Right Partner in Crime: Unlocking the Potential of the Anti-EGFR Antibody Cetuximab via Combination With Natural Killer Cell Chartering Immunotherapeutic Strategies
Cetuximab has an established role in the treatment of patients with recurrent/metastatic colorectal cancer and head and neck squamous cell cancer (HNSCC). However, the long-term effectiveness ofExpand
Exploring the key genes and pathways of osteosarcoma with pulmonary metastasis using a gene expression microarray
TLDR
Together, these data elucidated the molecular mechanisms of OS patients with pulmonary metastasis and provide potential therapeutic targets and further experimental studies are needed to confirm these results. Expand
Molecular targeted therapy of cancer: The progress and future prospect
TLDR
This review presents the application of molecule targeted therapy in cancer treatment and a particular focus is on the potential mechanism that can facilitate further improvement of anticancer. Expand
Pharmacogenetics and Personalized Medicine
TLDR
Despite the increasing complexity of pharmacogenetic analyses and their interpretation, some relationships between genetic biomarkers and treatment outcomes may be characterized by suboptimal values of sensitivity and specificity. Expand
Biomarkers of chondrosarcoma
TLDR
It is reported that angiogenesis and lymphangiogenesis increase by chondrosarcoma staging, and they are promoted by leptin and adiponectin, and several microRNAs to regulate vascular endothelial growth factor (VEGF)-A and VEGF-C are reported. Expand
A systematic comparison of label-free, SILAC and TMT techniques to study early adaption towards inhibition of EGFR signaling in the colorectal cancer cell line Difi.
TLDR
The EGFR signaling network is analyzed, and its dynamics within 24 h upon treatment with the EGFR blocking antibody cetuximab, representing the first cellular adaption towards therapy, are studied. Expand
...
1
2
...

References

SHOWING 1-10 OF 95 REFERENCES
EGFR ligands as pharmacodynamic biomarkers in metastatic colorectal cancer patients treated with cetuximab and irinotecan
TLDR
This hypothesis-generating study shows that EGFR ligands are significantly modulated by cetuximab plus irinotecan according to KRAS and BRAF mutational status, and they warrant further investigation as pharmacodynamic markers of resistance to anti-EGFRs. Expand
PIK3CA Mutations Are Not a Major Determinant of Resistance to the Epidermal Growth Factor Receptor Inhibitor Cetuximab in Metastatic Colorectal Cancer
TLDR
The findings do not provide any evidence for a strong role of PIK3CA mutations as a single marker in determining response to cetuximab in chemorefractory metastatic colorectal cancer. Expand
Is there a role for IGF1R and c-MET pathways in resistance to cetuximab in metastatic colorectal cancer?
TLDR
KRAS mutation significantly correlates with a worse outcome in patients treated with cetuximab, whereas no definitive inference can be drawn about the role of BRAF mutation and PTEN loss of expression and Interestingly, IGF1R overexpression seems a favorable prognostic factor in mCRC. Expand
Overexpression of MET is a new predictive marker for anti-EGFR therapy in metastatic colorectal cancer with wild-type KRAS
TLDR
The data point to the usefulness of MET overexpression, in addition to BRAF and PIK3CA mutations, as a new predictive marker for responsiveness to anti-EGFR MoAbs in mCRC patients with wild-type KRAS. Expand
EGFR gene copy number as a predictive biomarker for resistance to anti-EGFR monoclonal antibodies in metastatic colorectal cancer treatment: a meta-analysis.
OBJECTIVE The epidermal growth factor receptor (EGFR) inhibitors monoclonal antibodies (MoAbs) have already shown the therapeutic effectiveness in patients with metastatic colorectal cancer (mCRC).Expand
PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies.
TLDR
The mutational analysis of PIK3CA and KRAS and evaluation of the PTEN protein status in a cohort of 110 patients with mCRC treated with anti-EGFR moAbs indicate that Pik3CA mutations can independently hamper the therapeutic response to panitumumab or cetuximab in mC RC. Expand
Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer.
TLDR
The role of MET in mediating primary and secondary resistance to anti-EGFR therapies in colorectal cancer is highlighted and the use of MET inhibitors in patients displaying resistance as a result of MET amplification is encouraged. Expand
Heterogeneous EGFR Gene Copy Number Increase Is Common in Colorectal Cancer and Defines Response to Anti-EGFR Therapy
TLDR
IHC-guided EGFR GCN is a promising predictor of anti-EGFR treatment efficacy in chemorefractory CRC and was associated with AKT and ERK1/2 phosphorylation, which was effectively inhibited only in cells with KRAS-WT and increased EGFRGCN. Expand
MicroRNA signature in metastatic colorectal cancer patients treated with anti-EGFR monoclonal antibodies.
TLDR
The MiR-99a/Let-7c/miR-125b signature may improve the selection of patients with KRAS wild-type mCRC as good candidates for anti-EGFR therapy and is identified as a signature associated with an outcome different from that of anti- EGFR therapies. Expand
IGF2 is an actionable target that identifies a distinct subpopulation of colorectal cancer patients with marginal response to anti-EGFR therapies
TLDR
Rational combination therapies for colorectal cancer are suggested and evidence for IGF2 as a biomarker of reduced tumor sensitivity to anti-EGFR therapy and a determinant of response to combined IGF2/EGFR targeting is provided. Expand
...
1
2
3
4
5
...